Bioequivalence studies based on rate of exposure, not Cmax, under FDA consideration.
This article was originally published in The Tan Sheet
Executive Summary
RATE OF EXPOSURE MEASUREMENTS COULD REPLACE Cmax BIOEQUIVALENCE studies, FDA Division of Pharmaceutical Evaluation II Director Mei-Ling Chen, PhD, told FDA's Advisory Committee for Pharmaceutical Science June 23. "Instead of rate and extent of absorption" for determining bioequivalence, "you may characterize the drug's profile in terms of rate of exposure, which may be composed of three measures: total exposure, peak exposure and early exposure," Chen said.You may also be interested in...
People In Brief
Perrigo promotes in pricing, planning
In Brief
Combe sells most of its OTC brands
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: